Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of “Moderate Buy” by Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $11.13.

Several research analysts have issued reports on STRO shares. Piper Sandler restated an “overweight” rating and set a $11.00 price target on shares of Sutro Biopharma in a report on Friday, October 11th. JMP Securities restated a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a report on Monday, November 18th. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Sutro Biopharma in a research report on Tuesday, December 10th. Finally, Wells Fargo & Company cut their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th.

Institutional Investors Weigh In On Sutro Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in shares of Sutro Biopharma by 16.6% in the 4th quarter. SG Americas Securities LLC now owns 40,432 shares of the company’s stock worth $74,000 after purchasing an additional 5,770 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Sutro Biopharma in the third quarter valued at $77,000. Barclays PLC lifted its stake in shares of Sutro Biopharma by 385.3% in the third quarter. Barclays PLC now owns 273,019 shares of the company’s stock valued at $944,000 after buying an additional 216,757 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Sutro Biopharma by 7.7% during the third quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock valued at $6,426,000 after buying an additional 132,015 shares during the last quarter. Finally, XTX Topco Ltd increased its position in shares of Sutro Biopharma by 222.0% during the third quarter. XTX Topco Ltd now owns 104,200 shares of the company’s stock worth $361,000 after acquiring an additional 71,844 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Trading Up 3.0 %

Shares of STRO stock opened at $2.03 on Friday. The stock has a 50-day moving average of $2.22 and a 200-day moving average of $3.31. The stock has a market cap of $167.39 million, a price-to-earnings ratio of -1.26 and a beta of 1.15. Sutro Biopharma has a 1-year low of $1.67 and a 1-year high of $6.13.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.